Associated partners

The NANOMED curriculum benefits from the participation of experts from other Universities and private companies. Their roles are to provide with some courses/conferences and traineeship opportunities. Below is enclosed a non-extensive list of these partners:

Academic institutions:

  • Galien Institute, School of Pharmacy, University of Paris South (France)
  • University of Bourgogne (France)
  • University of Nantes (France)
  • Interuniversity Consortium TEFARCO Innova (Italy)
  • University of Roma Tor Vergata (Italy)
  • University of Athens (Greece)
  • Foundation of Research and Technology Hellas (FORTH, Greece)
  • University of Liège (Belgium)
  • Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra (Spain)
  • University of Granada (Spain)
  • University of Columbia, USA

Research Institutes:

  • Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, (FORTH / ICE-HT) (Greece)

Private companies:

  • French companies: CARLINA technologies, GATTEFOSSE, GUERBET, SANOFI.
  • Greek companies: DEMO PHARMACEUTICALS, ELPEN, VERISFIELD.
  • Bulgarian Company: Proxagen

Moreover, some Professional Associations are associated partners to the NANOMED consortium:

  • The European Technology Platform for Nanomedicine (ETPN) which gathers academic institutions and companies involved in the development of Nanomedicine in Europe at the research level but also at the educational level. The NANOMED programme has been built taking into account recommendations of the ETPN to ensure the best employability of the future EMJMD graduates.
  • The Society of Drug Delivery Sciences and Technology (APGI – Association de Pharmacie Galénique Industrielle), is a French association organizing European scientific meetings every year, with sessions dedicated to Nanomedicine. These meetings are gathering Academia members, private companies, regulatory bodies as well as colleagues from other scientific societies such as the Adritelf (Italian association for pharmaceutical technology and legislation).
  • The French Society of Nanomedicine (SF Nano) whose president, Dr. Nathalie Mignet, is the head of the French research team in Paris Descartes University.
  • The Greek Chapter of the Controlled Release Society and the Panhellenic Pharmaceutical Union (PEF) in Greece, which organize congresses in Pharmaceutical sciences.
  • The FORTH/ICE-HT Institute, Greece has a yearly seminar programme, which attracts many high-level international speakers.
  • The Italian chapter of the Controlled Release Society (CRS) and the Italian Association of Industrial Pharmacists (AFI), which organize international scientific conferences for academic and industrial professionals.
  • The NanoPharmaNet, a network connecting researchers having know-how and expertise on nanotechnologies for pharmaceutical and biomedical applications in Italy and promoting cooperation between research groups and members of Companies and the development of spin-offs.
  • The international congress on “Translational Nanomedicine” is a meeting gathering Academia members, private companies and regulatory agencies from different continents (North and South America, Asia, Africa, Australia and Europe).
  • The European programme NICHE is a collaborative research project within the Euronanomed 2 Programme. The NICHE project develops creative nanomedicines to propose a new treatment of pancreas cancer, based on the restoration and stimulation of immune competence in tumor-bearing hosts.
  • The European programme TRANS-INT is a large-scale collaborative research project within the 7th European Framework Program for Research and Technological Development. TRANS-INT combines expertise in pharmaceutical nanotechnology, biochemistry, immunology, toxicology, biology and physiology with the aim to develop a novel nanodrug candidate able to effectively fight diabetes. TRANSINT researchers will make use of nanotechnology to find new oral ways for drug delivery that can become an alternative to insulin injection, thus improving the quality of life of patients with diabetes.
  • The European programme FORMAMP is a collaborative research project within the 7th European Framework Program for Research and Technological Development. The aim of FORMAMP is to explore a number of innovative formulation and delivery strategies based on nanotechnology in order to improve the efficiency and stability of Antimicrobial peptides in clinical development.

Back to Top